<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829803</url>
  </required_header>
  <id_info>
    <org_study_id>SIS-SNAP-2008-01US</org_study_id>
    <nct_id>NCT00829803</nct_id>
  </id_info>
  <brief_title>A Study to Assess Indices of SNAP vs VISTA on Surgical Patients Undergoing General Anesthesia</brief_title>
  <acronym>Precision GA</acronym>
  <official_title>A Prospective Randomized Double Blinded Study Assessing Indices of SNAP vs VISTA on Surgical Patients Undergoing General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Instruments</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Instruments</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establish the range of index values for the SNAP II corresponding to each anesthetic state&#xD;
      studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Index values for the SNAP II monitor will be identified with each corresponding anesthetic&#xD;
      state studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SNAP Index values corresponding to anesthetic states: Pre-induction (baseline), loss of response, anesthesia maintenance, first purposeful response after anesthesia is discontinued, at extubation or LMA removal</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anesthesia, General</condition>
  <arm_group>
    <arm_group_label>SNAP Monitor EEG signals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIS Monitor EEG signals (VISTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SNAP monitor; Bispectral Index Monitor (BIS Monitor)</intervention_name>
    <description>Intended to monitor the state of the brain by data acquisition of EEG signals.</description>
    <arm_group_label>BIS Monitor EEG signals (VISTA)</arm_group_label>
    <arm_group_label>SNAP Monitor EEG signals</arm_group_label>
    <other_name>SNAP II monitor</other_name>
    <other_name>BIS Monitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for surgery requiring general anesthesia&#xD;
&#xD;
          -  Open or laparoscopic procedures&#xD;
&#xD;
          -  Cases anticipated to be less than 4 hours in duration&#xD;
&#xD;
          -  In-patient and out-patient subjects&#xD;
&#xD;
          -  Patients and cases manageable with LMA. Cases manageable with ET tube are also allowed&#xD;
             with the condition that only a minimal dose of short-acting NMBA is used at intubation&#xD;
             and not throughout the case.&#xD;
&#xD;
          -  Local analgesia at incision site is permitted.&#xD;
&#xD;
          -  Males and Females between 18 and 65 years of age, inclusive.&#xD;
&#xD;
          -  BMI&lt;40 and body mass&gt;41 kg&#xD;
&#xD;
          -  Patients who have signed the informed consent.&#xD;
&#xD;
          -  Able to receive Informed Consent through subjects native language providing that a&#xD;
             native language speaker delivers the Informed Consent.&#xD;
&#xD;
          -  ASA Stratification I - III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any subject failing to fulfill all inclusion criteria&#xD;
&#xD;
          -  ASA stratification &gt;= IV&#xD;
&#xD;
          -  Subject is a prisoner.&#xD;
&#xD;
          -  Patients presenting with evidence of recent trauma, active infection, neurological&#xD;
             disorder, seizure disorder, dementia or have been diagnosed with Alzheimer's disease&#xD;
&#xD;
          -  Subjects with cardiac or gastric pace makers&#xD;
&#xD;
          -  Pregnant women as identified by institutional SOP for female of child-bearing age&#xD;
&#xD;
          -  Patients that will not sign an informed consent form&#xD;
&#xD;
          -  Patients with previous adverse incidents with anesthesia, including awareness&#xD;
&#xD;
          -  Patients undergoing surgery on the head or neck&#xD;
&#xD;
          -  Subjects currently taking psychoactive medications as part of routine medical care&#xD;
             within the past 7 days&#xD;
&#xD;
          -  Subjects that require and/or receive any of the psychotherapeutic agents or&#xD;
             psychotropic drugs below, in the treatment of mental illness, and have taken such&#xD;
             treatment within the past 7 days.&#xD;
&#xD;
          -  Benzodiazepines&#xD;
&#xD;
          -  MAOI inhibitors&#xD;
&#xD;
          -  Selective serotonin reuptake inhibitors (SSRIs)&#xD;
&#xD;
          -  Tricyclic antidepressants&#xD;
&#xD;
          -  Lithium&#xD;
&#xD;
          -  Neuroleptic agents&#xD;
&#xD;
          -  Central nervous system stimulants.&#xD;
&#xD;
          -  Subjects with a known history of alcohol or narcotic abuse within 6 months prior to&#xD;
             screening OR subjects reporting narcotic or narcotic medication use with 24 hours&#xD;
             prior to surgery.&#xD;
&#xD;
          -  Subjects requiring neurophysiologic monitoring&#xD;
&#xD;
          -  Subjects requiring TIVA&#xD;
&#xD;
          -  Subjects requiring prolonged use of NMBA beyond dose required for intubation&#xD;
&#xD;
          -  Subjects requiring ketamine&#xD;
&#xD;
          -  Subjects receiving spinal, epidural, or other nerve blocks&#xD;
&#xD;
          -  Subjects having any condition or severe illness that to the Principal Investigator's&#xD;
             discretion would interfere with study assessments OR other severe acute or chronic&#xD;
             medical or psychiatric condition that may interfere with the interpretation of study&#xD;
             results and, in the judgment of the investigator, and would make the subject&#xD;
             inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio D Bergese, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101-6370</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>To acquire developmental data to prospectively support SNAP</keyword>
  <keyword>II index ranges at the studied anesthetic states.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

